ENTITY
Sciclone Pharmaceuticals

Sciclone Pharmaceuticals (6600 HK)

84
Analysis
Health CareChina
SciClone Pharmaceuticals (Holdings) Limited operates as a biopharmaceutical company. The Company develops produces and sells oncology drug, infectious diseases drugs and other products. SciClone Pharmaceuticals (Holdings) markets its products throughout China.
more
Refresh
24 May 2024 18:33

SciClone Pharma (6600 HK): Scheme Vote on 19 June

This is a done deal. At the last close and for the 12 July payment, the gross and annualised spread is 2.2% and 17.3%, respectively.

Logo
344 Views
Share
24 May 2024 09:40

SciClone Pharmaceuticals (6600 HK): 19th June Shareholder Vote

This is a clean privatisation. Assuming 12th July payment, I'd pay up to ~$18.45/share (~2%/15% gross/annualised spread).

Logo
324 Views
Share
02 Apr 2024 13:38

Sciclone Pharmaceuticals (6600.HK) - The Privatization Offers a Good Exit Opportunity

The success rate of privatization could be 70-80%. The time could be about six months. The annualized rate of return isn't attractive.It's up to...

Logo
343 Views
Share
01 Apr 2024 07:00

SciClone Pharma (6600 HK): Privatisation At IPO Price

This looks like a clean deal. The Offer is not contingent on specific regulatory approvals. Assuming late July payment, I'd pay up to ~$18/share.

Logo
521 Views
Share
01 Apr 2024 00:31

Merger Arb Mondays (01 Apr) - SciClone, IntelliCentrics, CIMC Vehicles, Lawson, Roland DG, MMA

This week, the highest gross spreads are SciClone (17.2%), Qantm IP (15.0%), Genex Power (12.2%), Southern Cross (11.2%), China TCM (7.5%), QV...

Logo
383 Views
Share
x